ABVX
Abivax S.A.
Biotechnology
Market Cap$6.61B
5Y Perf.+949.5%
Build Your Comparison
Side-by-side financial analysisABVX
PTGX
Try popular comparisons:
Stock Comparison
ABVX vs PTGX
Revenue, margins, valuation, and 5-year total return — side by side.
PTGX
Protagonist Therapeutics, Inc.
Biotechnology
Market Cap$7.06B
5Y Perf.+584.7%
ABVX vs PTGX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  ABVX |  PTGX |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $6.61B | $7.06B |
| Revenue (TTM) | $0.00 | $18M |
| Net Income (TTM) | $-427M | $-115M |
| Gross Margin | — | 100.0% |
| Operating Margin | — | -8.1% |
| Forward P/E | — | 27.2x |
| Total Debt | $32M | $10M |
| Cash & Equiv. | $516M | $128M |
ABVX vs PTGX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ABVX
PTGX
| Stock | Oct 23 | Jun 26 | Return |
|---|---|---|---|
| Abivax S.A. (ABVX) | 100 | 1049.5 | +949.5% |
| Protagonist Therape… (PTGX) | 100 | 684.7 | +584.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ABVX vs PTGX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: PTGX leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Abivax S.A. is the stronger pick specifically for profitability and margin quality and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
🥇PTGX emerged as the overall leader. Track its performance:
ABVX
Abivax S.A.
The Long-Run Compounder
ABVX is the clearest fit if your priority is long-term compounding.
- 11.2% 10Y total return vs PTGX's 8.4%
- -3.9% margin vs PTGX's -6.5%
- +12.6% vs PTGX's +98.4%
Best for: long-term compounding
PTGX
Protagonist Therapeutics, Inc.
The Income Pick
PTGX carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.25
- Rev growth -89.4%, EPS growth -148.5%, 3Y rev CAGR 20.1%
- Lower volatility, beta 0.25, Low D/E 1.7%, current ratio 12.71x
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  PTGX | -89.4% revenue growth vs ABVX's -100.0% |
| Quality / Margins |  ABVX | -3.9% margin vs PTGX's -6.5% |
| Stability / Safety | PTGX | Beta 0.25 vs ABVX's 1.02, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ABVX | +12.6% vs PTGX's +98.4% |
| Efficiency (ROA) | PTGX | -16.5% ROA vs ABVX's -143.2% |
ABVX vs PTGX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2024
ABVX vs PTGX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLPTGXLAGGINGABVX
ABVXAbivax S.A.
1leads
PTGXProtagonist Therapeut…
4leads
6 Total Categories
CATEGORYLEADERvs ABVXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
PTGX1/1
Valuation MetricsMultiples, price ratios, and targets
PTGX2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
PTGX6/7
Total Returns1Y, 3Y, 5Y total returns with dividends
ABVX5/6
Risk & VolatilityBeta, volatility, and downside exposure
PTGX2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
PTGX leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
PTGX and ABVX operate at a comparable scale, with $18M and $0 in trailing revenue.
| Metric | ABVXAbivax S.A. | PTGXProtagonist Thera… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $18M |
| EBITDAEarnings before interest/tax | -$327M | -$141M |
| Net IncomeAfter-tax profit | -$427M | -$115M |
| Free Cash FlowCash after capex | -$250M | -$116M |
| Gross MarginGross profit ÷ Revenue | — | +100.0% |
| Operating MarginEBIT ÷ Revenue | — | -8.1% |
| Net MarginNet income ÷ Revenue | — | -6.5% |
| FCF MarginFCF ÷ Revenue | — | -6.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -100.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -40.0% | +126.3% |
PTGX leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
PTGX leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | ABVXAbivax S.A. | PTGXProtagonist Thera… |
|---|---|---|
| Market CapShares × price | $6.6B | $7.1B |
| Enterprise ValueMkt cap + debt − cash | $6.1B | $6.9B |
| Trailing P/EPrice ÷ TTM EPS | -18.79x | -53.56x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 27.22x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 153.44x |
| Price / BookPrice ÷ Book value/share | 13.35x | 11.35x |
| Price / FCFMarket cap ÷ FCF | — | 125.90x |
PTGX leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
PTGX leads this category, winning 6 of 7 comparable metrics.
Profitability & Efficiency
PTGX delivers a -17.8% return on equity — every $100 of shareholder capital generates $-18 in annual profit, vs $-3 for ABVX. PTGX carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to ABVX's 0.07x. On the Piotroski fundamental quality scale (0–9), PTGX scores 4/9 vs ABVX's 3/9, reflecting mixed financial health.
| Metric | ABVXAbivax S.A. | PTGXProtagonist Thera… |
|---|---|---|
| ROE (TTM)Return on equity | -3.0% | -17.8% |
| ROA (TTM)Return on assets | -143.2% | -16.5% |
| ROICReturn on invested capital | — | -21.8% |
| ROCEReturn on capital employed | -77.7% | -23.9% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | 0.07x | 0.02x |
| Net DebtTotal debt minus cash | -$484M | -$118M |
| Cash & Equiv.Liquid assets | $516M | $128M |
| Total DebtShort + long-term debt | $32M | $10M |
| Interest CoverageEBIT ÷ Interest expense | -14.16x | — |
PTGX leads this category, winning 6 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
ABVX leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ABVX five years ago would be worth $121,530 today (with dividends reinvested), compared to $27,697 for PTGX. Over the past 12 months, ABVX leads with a +1259.4% total return vs PTGX's +98.4%. The 3-year compound annual growth rate (CAGR) favors ABVX at 129.9% vs PTGX's 55.9% — a key indicator of consistent wealth creation.
| Metric | ABVXAbivax S.A. | PTGXProtagonist Thera… |
|---|---|---|
| YTD ReturnYear-to-date | -24.6% | +25.9% |
| 1-Year ReturnPast 12 months | +1259.4% | +98.4% |
| 3-Year ReturnCumulative with dividends | +1115.3% | +278.8% |
| 5-Year ReturnCumulative with dividends | +1115.3% | +177.0% |
| 10-Year ReturnCumulative with dividends | +1115.3% | +838.4% |
| CAGR (3Y)Annualised 3-year return | +129.9% | +55.9% |
ABVX leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
PTGX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
PTGX is the less volatile stock with a 0.25 beta — it tends to amplify market swings less than ABVX's 1.02 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PTGX currently trades 98.5% from its 52-week high vs ABVX's 67.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ABVXAbivax S.A. | PTGXProtagonist Thera… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.02x | 0.25x |
| 52-Week HighHighest price in past year | $148.83 | $111.45 |
| 52-Week LowLowest price in past year | $5.69 | $49.38 |
| % of 52W HighCurrent price vs 52-week peak | +67.8% | +98.5% |
| RSI (14)Momentum oscillator 0–100 | 41.9 | 57.4 |
| Avg Volume (50D)Average daily shares traded | 1.5M | 572K |
PTGX leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates ABVX as "Buy" and PTGX as "Buy". Consensus price targets imply 30.1% upside for ABVX (target: $131) vs 5.1% for PTGX (target: $115).
| Metric | ABVXAbivax S.A. | PTGXProtagonist Thera… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $131.22 | $115.40 |
| # AnalystsCovering analysts | 12 | 26 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
PTGX leads in 4 of 6 categories (Income & Cash Flow, Valuation Metrics). ABVX leads in 1 (Total Returns).
Best OverallProtagonist Therapeutics, I… (PTGX)Leads 4 of 6 categories
Loading custom metrics...
ABVX vs PTGX: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is ABVX or PTGX a better buy right now?
Analysts rate Abivax S.
A. (ABVX) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ABVX or PTGX?
Over the past 5 years, Abivax S.
A. (ABVX) delivered a total return of +1115%, compared to +177. 0% for Protagonist Therapeutics, Inc. (PTGX). Over 10 years, the gap is even starker: ABVX returned +1115% versus PTGX's +838. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ABVX or PTGX?
By beta (market sensitivity over 5 years), Protagonist Therapeutics, Inc.
(PTGX) is the lower-risk stock at 0. 25β versus Abivax S. A. 's 1. 02β — meaning ABVX is approximately 307% more volatile than PTGX relative to the S&P 500. On balance sheet safety, Protagonist Therapeutics, Inc. (PTGX) carries a lower debt/equity ratio of 2% versus 7% for Abivax S. A. — giving it more financial flexibility in a downturn.
04Which is growing faster — ABVX or PTGX?
On earnings-per-share growth, the picture is similar: Abivax S.
A. grew EPS -66. 1% year-over-year, compared to -148. 5% for Protagonist Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ABVX or PTGX?
Abivax S.
A. (ABVX) is the more profitable company, earning 0. 0% net margin versus -282. 8% for Protagonist Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABVX leads at 0. 0% versus -343. 6% for PTGX. At the gross margin level — before operating expenses — PTGX leads at 97. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is ABVX or PTGX more undervalued right now?
Analyst consensus price targets imply the most upside for ABVX: 30.
1% to $131. 22.
07Which pays a better dividend — ABVX or PTGX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is ABVX or PTGX better for a retirement portfolio?
For long-horizon retirement investors, Protagonist Therapeutics, Inc.
(PTGX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 25), +838. 4% 10Y return). Both have compounded well over 10 years (PTGX: +838. 4%, ABVX: +1115%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between ABVX and PTGX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.